Krystal Biotech saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 80 to 84.
This proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
History reveals that the market's biggest winners often have an 80 or better RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
While Krystal Biotech is not near an ideal buy point right now, see if it goes on to form and break out of a proper base.
While sales growth fell last quarter from 879% to 116%, the bottom line grew 407%, up from 0% in the previous report.
Krystal Biotech earns the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. United Therapeutics and Catalyst Pharmaceuticals are also among the group's highest-rated stocks.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
